Home » Stocks » NVUS

Novus Therapeutics, Inc. (NVUS)

Jan 5, 2021 - Stock symbol was changed to ELDN
Stock Price: $14.60 USD -0.80 (-5.19%)
Updated Jan 4, 2021 4:00 PM EST
Market Cap 20.97M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 1.44M
EPS (ttm) -22.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Jan 4, 2021
Last Price $14.60
Previous Close $15.40
Change ($) -0.80
Change (%) -5.19%
Day's Open -
Day's Range 14.60 - 15.77
Day's Volume 0
52-Week Range 4.68 - 26.18

News

Hide News
GlobeNewsWire - 2 weeks ago

Eledon to commence trading on the Nasdaq exchange under the ticker “ELDN” effective tomorrow, January 5, 2021

Business Wire - 1 month ago

IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics announced the appointment of June Lee, M.D., to the company's Board of Directors.

Seeking Alpha - 2 months ago

Novus Therapeutics, Inc. (NVUS) CEO David-Alexandre Gros on Q3 2020 Results - Earnings Call Transcript

Business Wire - 2 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patie...

Business Wire - 2 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patie...

Business Wire - 2 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis

Zacks Investment Research - 3 months ago

Novus Therapeutics is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Business Wire - 3 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split

Zacks Investment Research - 3 months ago

The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.

Other stocks mentioned: BBC, BTEC, IBBJ, IDNA, MRNS, PTH, SAVA, WVE
Business Wire - 4 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics to Present at H.C.

Seeking Alpha - 4 months ago

Novus Therapeutics, Inc. (NVUS) CEO Dr.

Business Wire - 4 months ago

IRVINE, Calif. & BOSTON--(BUSINESS WIRE)--Novus Therapeutics Announces Acquisition of Anelixis Therapeutics

Benzinga - 7 months ago

Novus Therapeutics (NASDAQ: NVUS) shares are trading lower on Tuesday. Ladenburg Thalmann downgraded the stock from Buy to Neutral and announced a price target of 60 cents per share.

Market Watch - 7 months ago

Shares of Novus Therapeutics Inc. NVUS, -49.60% lost nearly half their value in active trading Monday, after the specialty drug maker announced disappointing trial results of its ear infection...

About NVUS

Novus Therapeutics, a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, Cali... [Read more...]

Industry
Biotechnology
Founded
2004
CEO
Gregory Flesher
Employees
7
Stock Exchange
NASDAQ
Ticker Symbol
NVUS
Full Company Profile

Financial Performance

Financial Statements